Epidermal growth factor receptor-targeted therapy in locally advanced or metastatic squamous cell carcinoma of the penis

Bradley C. Carthon, Chaan S. Ng, Curtis A. Pettaway, Lance C. Pagliaro

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Objective To evaluate the safety and efficacy of epidermal growth factor receptor (EGFR)-targeted therapy in patients with advanced penile or scrotal cancer. Patients and Methods We retrospectively reviewed the charts of patients with penile or scrotal squamous cell carcinoma who had visited our tertiary cancer centre between 2002 and 2009, including their subsequent treatment and follow-up. We collected details of EGFR-targeted therapy and clinical outcomes. Treatment-associated time-to-disease-progression (TTP), overall survival (OS), responses to therapy and toxicity were evaluated. Results A total of 24 patients had received EGFR-targeted therapies, including cetuximab, erlotinib and gefitinib. The most common treatment given (to 67% of patients) was cetuximab combined with one or more cytotoxic drugs. The most common adverse effect was skin rash (71%). The median (range) TTP and OS were 11.3 (1-40) and 29.6 (2-205) weeks, respectively. The OS time for patients with visceral or bone metastases was significantly shorter than it was for those without (24.7 vs 49.9 weeks, P = 0.013). Among 17 patients treated with cetuximab alone or in combination with cisplatin, there were four partial responses (23.5%) including two patients with apparently chemotherapy-resistant tumours. Conclusions Our results suggest that cetuximab has antitumour activity in metastatic penile cancer, and may enhance the effect of cisplatin-based chemotherapy. Prospective studies of EGFR-targeted therapies in men with these tumours are warranted.

Original languageEnglish (US)
Pages (from-to)871-877
Number of pages7
JournalBJU International
Volume113
Issue number6
DOIs
StatePublished - 2014
Externally publishedYes

Fingerprint

Penis
Epidermal Growth Factor Receptor
Squamous Cell Carcinoma
Therapeutics
Cisplatin
Survival
Disease Progression
Neoplasms
Penile Neoplasms
Drug Therapy
Exanthema
Prospective Studies
Neoplasm Metastasis
Safety
Bone and Bones
Cetuximab
Pharmaceutical Preparations

Keywords

  • anti-epidermal growth factor monoclonal antibody
  • penile neoplasms
  • squamous cell carcinoma
  • survival

ASJC Scopus subject areas

  • Urology

Cite this

Epidermal growth factor receptor-targeted therapy in locally advanced or metastatic squamous cell carcinoma of the penis. / Carthon, Bradley C.; Ng, Chaan S.; Pettaway, Curtis A.; Pagliaro, Lance C.

In: BJU International, Vol. 113, No. 6, 2014, p. 871-877.

Research output: Contribution to journalArticle

Carthon, Bradley C. ; Ng, Chaan S. ; Pettaway, Curtis A. ; Pagliaro, Lance C. / Epidermal growth factor receptor-targeted therapy in locally advanced or metastatic squamous cell carcinoma of the penis. In: BJU International. 2014 ; Vol. 113, No. 6. pp. 871-877.
@article{6c393f87392340939e85903581729ec8,
title = "Epidermal growth factor receptor-targeted therapy in locally advanced or metastatic squamous cell carcinoma of the penis",
abstract = "Objective To evaluate the safety and efficacy of epidermal growth factor receptor (EGFR)-targeted therapy in patients with advanced penile or scrotal cancer. Patients and Methods We retrospectively reviewed the charts of patients with penile or scrotal squamous cell carcinoma who had visited our tertiary cancer centre between 2002 and 2009, including their subsequent treatment and follow-up. We collected details of EGFR-targeted therapy and clinical outcomes. Treatment-associated time-to-disease-progression (TTP), overall survival (OS), responses to therapy and toxicity were evaluated. Results A total of 24 patients had received EGFR-targeted therapies, including cetuximab, erlotinib and gefitinib. The most common treatment given (to 67{\%} of patients) was cetuximab combined with one or more cytotoxic drugs. The most common adverse effect was skin rash (71{\%}). The median (range) TTP and OS were 11.3 (1-40) and 29.6 (2-205) weeks, respectively. The OS time for patients with visceral or bone metastases was significantly shorter than it was for those without (24.7 vs 49.9 weeks, P = 0.013). Among 17 patients treated with cetuximab alone or in combination with cisplatin, there were four partial responses (23.5{\%}) including two patients with apparently chemotherapy-resistant tumours. Conclusions Our results suggest that cetuximab has antitumour activity in metastatic penile cancer, and may enhance the effect of cisplatin-based chemotherapy. Prospective studies of EGFR-targeted therapies in men with these tumours are warranted.",
keywords = "anti-epidermal growth factor monoclonal antibody, penile neoplasms, squamous cell carcinoma, survival",
author = "Carthon, {Bradley C.} and Ng, {Chaan S.} and Pettaway, {Curtis A.} and Pagliaro, {Lance C.}",
year = "2014",
doi = "10.1111/bju.12450",
language = "English (US)",
volume = "113",
pages = "871--877",
journal = "BJU International",
issn = "1464-4096",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Epidermal growth factor receptor-targeted therapy in locally advanced or metastatic squamous cell carcinoma of the penis

AU - Carthon, Bradley C.

AU - Ng, Chaan S.

AU - Pettaway, Curtis A.

AU - Pagliaro, Lance C.

PY - 2014

Y1 - 2014

N2 - Objective To evaluate the safety and efficacy of epidermal growth factor receptor (EGFR)-targeted therapy in patients with advanced penile or scrotal cancer. Patients and Methods We retrospectively reviewed the charts of patients with penile or scrotal squamous cell carcinoma who had visited our tertiary cancer centre between 2002 and 2009, including their subsequent treatment and follow-up. We collected details of EGFR-targeted therapy and clinical outcomes. Treatment-associated time-to-disease-progression (TTP), overall survival (OS), responses to therapy and toxicity were evaluated. Results A total of 24 patients had received EGFR-targeted therapies, including cetuximab, erlotinib and gefitinib. The most common treatment given (to 67% of patients) was cetuximab combined with one or more cytotoxic drugs. The most common adverse effect was skin rash (71%). The median (range) TTP and OS were 11.3 (1-40) and 29.6 (2-205) weeks, respectively. The OS time for patients with visceral or bone metastases was significantly shorter than it was for those without (24.7 vs 49.9 weeks, P = 0.013). Among 17 patients treated with cetuximab alone or in combination with cisplatin, there were four partial responses (23.5%) including two patients with apparently chemotherapy-resistant tumours. Conclusions Our results suggest that cetuximab has antitumour activity in metastatic penile cancer, and may enhance the effect of cisplatin-based chemotherapy. Prospective studies of EGFR-targeted therapies in men with these tumours are warranted.

AB - Objective To evaluate the safety and efficacy of epidermal growth factor receptor (EGFR)-targeted therapy in patients with advanced penile or scrotal cancer. Patients and Methods We retrospectively reviewed the charts of patients with penile or scrotal squamous cell carcinoma who had visited our tertiary cancer centre between 2002 and 2009, including their subsequent treatment and follow-up. We collected details of EGFR-targeted therapy and clinical outcomes. Treatment-associated time-to-disease-progression (TTP), overall survival (OS), responses to therapy and toxicity were evaluated. Results A total of 24 patients had received EGFR-targeted therapies, including cetuximab, erlotinib and gefitinib. The most common treatment given (to 67% of patients) was cetuximab combined with one or more cytotoxic drugs. The most common adverse effect was skin rash (71%). The median (range) TTP and OS were 11.3 (1-40) and 29.6 (2-205) weeks, respectively. The OS time for patients with visceral or bone metastases was significantly shorter than it was for those without (24.7 vs 49.9 weeks, P = 0.013). Among 17 patients treated with cetuximab alone or in combination with cisplatin, there were four partial responses (23.5%) including two patients with apparently chemotherapy-resistant tumours. Conclusions Our results suggest that cetuximab has antitumour activity in metastatic penile cancer, and may enhance the effect of cisplatin-based chemotherapy. Prospective studies of EGFR-targeted therapies in men with these tumours are warranted.

KW - anti-epidermal growth factor monoclonal antibody

KW - penile neoplasms

KW - squamous cell carcinoma

KW - survival

UR - http://www.scopus.com/inward/record.url?scp=84891915793&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84891915793&partnerID=8YFLogxK

U2 - 10.1111/bju.12450

DO - 10.1111/bju.12450

M3 - Article

C2 - 24053151

AN - SCOPUS:84891915793

VL - 113

SP - 871

EP - 877

JO - BJU International

JF - BJU International

SN - 1464-4096

IS - 6

ER -